As reported in the Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine by Jason D. Merker, MD, PhD, of Stanford University School of Medicine, and colleagues, ASCO and the College of American Pathologists (CAP) have issued a joint review on the status of circulating tumor DNA (ctDNA) testing in patients with solid tumors. The review was motivated by recognition that clinical use of analytic tests to assess genomic variants in ctDNA is increasing and that guidelines for use will be required in the near future. The review was informed by an expert panel literature review on the use of ctDNA assays for solid tumors, including preanalytic variables; analytic validity; interpretation and reporting; and clinical validity and utility. The panel was co-chaired by Dr. Merker (CAP representative) and by Nicholas C. Turner, MD, PhD (ASCO representative), of the Royal Marsden Hospital and the Institute of Cancer Research.
Key Elements
Key elements of the review are summarized/reproduced here:
Tom Oliver, of ASCO, is the corresponding author of the Journal of Clinical Oncology article. e-mail: guidelines@asco.org.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.